The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-ϰB.
The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB.
US8252942B2
申请人:——
公开号:US8252942B2
公开(公告)日:2012-08-28
A Palladium-Catalyzed Multicomponent Synthesis of Imidazolinium Salts and Imidazolines from Imines, Acid Chlorides, and Carbon Monoxide
作者:Kraig Worrall、Boran Xu、Sébastien Bontemps、Bruce A. Arndtsen
DOI:10.1021/jo101858d
日期:2011.1.7
imidazolinium carboxylates and imidazolines is described. The palladium catalyst [Pd(CH(R1)N(R2)COR3)Cl]2, or [Pd(allyl)Cl]2, with P(t-Bu)2(2-biphenyl) can mediate the simultaneous coupling of two imines, acid chloride, and carbon monoxide into substituted imidazolinium carboxylates within hours under mild conditions (45 °C, 4 atm of CO). The reaction proceeds in good yield with aryl-, heteroaryl-, and alkyl-substituted